Full Press Release Details
regeneron to highlight advances at asco with phase 3 adjuvant libtayo cemiplimab cscc updates and promising early blood cancer data with linvoseltamab combination.
REGN
regeneron to highlight advances at asco with phase 3 adjuvant libtayo cemiplimab cscc updates and promising early blood cancer data with linvoseltamab combination
Key Takeaway: regeneron to highlight advances at asco with phase 3 adjuvant libtayo cemiplimab cscc updates and promising early blood cancer data with linvoseltamab combination